{"filing":{"accession_number":"0001683168-26-005656","cik":"0001402328","ticker":"SBFMW","company_name":"Sunshine Biopharma Inc.","form":"8-K","filing_date":"2026-07-20","report_date":null,"primary_document":"sunshine_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826005656/sunshine_8k.htm"},"events":[{"id":18818,"run_id":16930,"accession_number":"0001683168-26-005656","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Sunshine Biopharma entered into an At-The-Market (ATM) Issuance Sales Agreement on July 20, 2026, authorizing the sale of up to $4,000,000 in common stock shares through Aegis Capital Corp. ATM offerings are unregistered equity issuances that create dilution to existing shareholders and are a material capital-raising mechanism, particularly for smaller biotech companies. The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement), confirming materiality.","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17741,"accession_number":"0001683168-26-005656","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Sunshine Biopharma entered into an At-The-Market (ATM) Issuance Sales Agreement on July 20, 2026, authorizing the sale of up to $4,000,000 in common stock shares through Aegis Capital Corp. ATM offerings are unregistered equity issuances that create dilution to existing shareholders and are a material capital-raising mechanism, particularly for smaller biotech companies. The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement), confirming materiality.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:28:36.729516+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17741,"accession_number":"0001683168-26-005656","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Sunshine Biopharma entered into an At-The-Market (ATM) Issuance Sales Agreement on July 20, 2026, authorizing the sale of up to $4,000,000 in common stock shares through Aegis Capital Corp. ATM offerings are unregistered equity issuances that create dilution to existing shareholders and are a material capital-raising mechanism, particularly for smaller biotech companies. The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement), confirming materiality.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:28:36.729516+00:00","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-07-20"}]}